Hims & Hers Falls 11% After FDA Announces Shortage Has Ended for Eli Lilly Drugs
Hims & Hers Falls 11% After FDA Announces Shortage Has Ended for Eli Lilly Drugs
Hims & Hers 股价下跌11%，FDA宣布Eli Lilly药物短缺已结束
$Hims & Hers Health (HIMS.US)$ dropped 11% after the Food and Drug Administration announced shortages of Eli Lilly's obesity and diabetes drugs Zepbound and Mounjaro have ended.
$Hims & Hers Health (HIMS.US)$ 在美国食品药品监督管理局宣布Eli Lilly的肥胖和糖尿病药物Zepbound和Mounjaro的短缺问题已经解决后，其股价下跌了11%。
The company sells direct-to-consumer generic prescription medicines, including weight-loss drugs, and with Lilly's shortages, had taken advantage by creating copycat treatments.
该公司销售直接面向消费者的通用处方药，包括减肥药，在Eli Lilly药物短缺的情况下，通过开发仿制药获利。
Investors will keep their eyes on the upcoming Hims & Hers Health earnings report. Prior to Thursday's news, shares had increased 33.17% in the last month.
投资者将继续关注即将发布的Hims & Hers Health收益报告。在周四的消息之前，股价在过去一个月已上涨33.17%。
资讯热榜
更新时间